European Pharmaceutical Review
SEPTEMBER 1, 2023
The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. percent share by 2029, the research has shown. If successful, this trial will mark the first time an mRNA cancer vaccine and an immune checkpoint inhibitor have shown improved recurrence-free survival rates.
European Pharmaceutical Review
MAY 7, 2024
percent compound annual growth rate (CAGR) between 2024 to 2029. billion by 2029. Injectable vaccines activate the immune system to help to prevent infectious conditions such as influenza. by 2029 appeared first on European Pharmaceutical Review. The market is anticipated to value $1139.4 Eli Lilly and Company and Sandoz.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 12, 2023
In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. CB1 is predominantly found in the central and peripheral nervous system, whereas CB2 is primarily located in immune cells.
pharmaphorum
NOVEMBER 18, 2022
Dr John Lin, senior vice president of immune-oncology and head of bispecifics at Regeneron , said: “The collaboration will enable Regeneron and CytomX to combine our collective oncology expertise with two premier platforms […] to develop novel immunotherapies and research their potential to transform patient lives.”.
European Pharmaceutical Review
JANUARY 2, 2024
According to the research, the global cell and gene therapy market is predicted to value $80 billion by 2029. AstraZeneca highlighted that beneficially, the Gracell FasTCAR platform significantly shortens manufacturing time, enhances T cell fitness and could improve the effectiveness of autologous CAR-T treatment in patients.
The Checkup by Singlecare
MAY 17, 2024
Enbrel (etanercept), is a brand-name biologic drug that blocks the activity of tumor necrosis factor (TNF) , a substance in the body that can cause inflammation and lead to immune system diseases. They target the same molecule but look very different to the immune system.”
European Pharmaceutical Review
AUGUST 30, 2022
1 This novel approach has been found to trigger robust protective immune responses at the predominant sites of pathogen infection. million by 2029, up from $122.287 million in 2021. Recent studies indicate that mucosal delivery of vaccines provides a better, longer-lasting effect than the traditional injection route.
Expert insights. Personalized for you.
110 
Let's personalize your content